Randy R Miller

发表

In Vitro Drug Metabolism

Wei Tang, Randy R Miller, 2004 .

Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor.

Rebecca T. Ruck, Yongxin Han, J. Howe, 2016, ACS medicinal chemistry letters.

Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A Inhibitors.

J. Howe, Zhuyan Guo, I. Davies, 2016, ACS medicinal chemistry letters.

Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.

Howard Y. Chen, R. Nargund, M. Wyvratt, 2010, Bioorganic & medicinal chemistry letters.

Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity.

M. Reibarkh, Howard Y. Chen, R. Nargund, 2010, Bioorganic & medicinal chemistry letters.

Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder.

M. Struthers, R. Berger, C. Moyes, 2017, Bioorganic & medicinal chemistry letters.

Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist.

D. Macintyre, Howard Y. Chen, R. Nargund, 2010, Bioorganic & medicinal chemistry letters.

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

M. Struthers, R. Berger, C. Moyes, 2016, Journal of medicinal chemistry.

Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.

Jeffrey T. Kuethe, J. Demartino, E. Sherer, 2016, Journal of medicinal chemistry.

Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist.

J. Metzger, D. Macintyre, L. V. D. van der Ploeg, 2005, Bioorganic & Medicinal Chemistry Letters.

Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.

D. Macintyre, Howard Y. Chen, R. Nargund, 2011, Bioorganic & medicinal chemistry letters.

Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands.

J. Metzger, L. V. D. van der Ploeg, C. Rosenblum, 2010, Bioorganic & medicinal chemistry letters.

1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: application in the synthesis of potent human melanocortin-4 receptor selective agonists.

L. V. D. van der Ploeg, A. Patchett, R. Nargund, 2005, Bioorganic & medicinal chemistry letters.

Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity.

M. Reitman, J. Metzger, Yan Dong, 2010, Cell metabolism.

Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.

M. Reitman, J. Metzger, O. Palyha, 2011, ACS medicinal chemistry letters.

The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.

V. Hornak, W. Schafer, C. Welch, 2012, Bioorganic & Medicinal Chemistry.

Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.

V. Hornak, W. Schafer, C. Welch, 2011, ACS medicinal chemistry letters.

Discovery of benzamides as potent human β3 adrenergic receptor agonists.

M. Struthers, A. Weber, G. Salituro, 2016, Bioorganic & medicinal chemistry letters.

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.

D. Johnston, D. Macintyre, L. V. D. van der Ploeg, 2002, Journal of medicinal chemistry.

Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.

M. Reitman, J. Metzger, O. Palyha, 2011, ACS medicinal chemistry letters.

Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.

C. Raab, W. Geissler, H. Wood, 2020, Journal of medicinal chemistry.

Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.

R. Miller, J. Lin, B. Arison, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.

Howard Y. Chen, R. Nargund, M. Wyvratt, 2010, Bioorganic & Medicinal Chemistry Letters.